Following its success in lung cancer, as well as in other types of cancer, PD-L1 has recently gained attention as a predictive biomarker for immunotherapy response in triple negative breast cancer and other subtypes of breast cancer3–5. This evidence concerns the gene CD274 and triple-negative breast carcinoma.